Cytocom, Inc.: directors' dealings · United States · SEC (Form 4)

About Cytocom, Inc.

Cytocom, Inc. (ticker: CBLI) was a U.S.-based biopharmaceutical company whose investment case was centered on immune-modulation and related therapeutic development. For French-speaking investors, the key market reference is that CBLI traded on NASDAQ in the United States, placing it within the highly speculative small-cap biotech universe rather than a mature commercial pharma peer group. SEC materials describe Cytocom as a development-stage company focused on building and advancing a portfolio of therapeutic candidates, with an emphasis on immune homeostasis, inflammation-related disease areas, and oncology-adjacent applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921019964/cbli20210630_10q.htm?utm_source=openai)) The company’s history is closely tied to corporate restructuring. In July 2021, Cleveland BioLabs completed its merger with Cytocom, and the combined company began trading under the CBLI symbol on NASDAQ. Subsequent SEC disclosures show that the corporate identity associated with Cytocom was later changed again to Statera Biopharma, underscoring that Cytocom’s standalone branding was part of a transitional phase in a broader reorganization. In other words, CBLI is best understood as a reorganized biotech platform rather than a long-established operating pharmaceutical franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774922006873/cbli20220220_424b5.htm?utm_source=openai)) Operationally, Cytocom’s model was built around research, clinical development, and the potential commercialization of pre-revenue drug candidates. SEC filings reference activities conducted through subsidiaries such as ImQuest Life Sciences, ImQuest BioSciences, ImQuest Pharmaceuticals, and Lubrinovation, which points to a portfolio structure typical of early-stage biotechnology companies. The company’s disclosures indicate exposure to candidates and programs targeting immune regulation, with the broader goal of translating scientific assets into regulated therapeutic products. That profile implies a business driven by pipeline milestones rather than by recurring product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921019964/cbli20210630_10q.htm?utm_source=openai)) From a competitive standpoint, Cytocom operated in one of the most crowded and capital-intensive areas of healthcare. Its competitive position depended less on scale and more on scientific differentiation, intellectual property, clinical data, and the ability to secure financing or strategic partnerships. Compared with large-cap biopharma groups, Cytocom had limited commercial infrastructure and a much higher dependence on external capital, making the stock especially sensitive to trial updates, balance-sheet changes, and insider transaction filings under SEC Form 4. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921017701/ex_268327.htm?utm_source=openai)) Recent developments available in the SEC record are more about corporate transformation than about commercial launch execution. For investors, that means the most relevant diligence points are the state of the pipeline, financing needs, and the significance of any insider activity disclosed on Form 4. Overall, Cytocom was a United States biotech issuer quoted on NASDAQ whose story was defined by restructuring, development-stage assets, and high execution risk rather than by an established marketed-product base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921019964/cbli20210630_10q.htm?utm_source=openai))